PRINCETON, N.J. — Taiho Oncology Inc., a company focused on developing and commercializing novel treatments for hematologic malignancies and solid tumors, said Peter Melnyk has joined the company as President and Chief Operating Officer.
Melnyk brings more than 30 years of experience in oncology commercialization and leadership across the pharmaceutical, medical device, and biotechnology sectors. He most recently served as Chief Commercial Officer at Alpha Tau Medical, where he also previously sat on the board and led global commercialization efforts for a novel alpha-emitting radiotherapeutic.
Earlier in his career, Melnyk was Chief Executive Officer of Fortovia Therapeutics, where he led the company’s transformation and expansion of its oncology supportive care portfolio. He also served as Chief Commercial Officer at Novocure, building the company’s global commercial infrastructure and leading the launch of Optune, a medical device therapy for glioblastoma. His prior roles include senior leadership positions at OSI/Astellas, Pharmacia/Pfizer, and Bristol-Myers Squibb. Melnyk holds both a Master of Science and a Bachelor of Science from McGill University.
“We are excited to welcome Peter to Taiho Oncology as President & Chief Operating Officer,” said Tim Whitten, CEO of Taiho Oncology. “Peter is an innovator with a demonstrated track record of success. We believe his strong leadership capabilities and ability to deliver measurable results will help guide Taiho Oncology’s continued growth and innovation as we pursue our mission of improving the lives of patients with cancer, their families and their caregivers.”
“It’s a privilege to join Taiho Oncology, a company with a remarkable legacy of scientific innovation, commercial excellence, patient-centered care and an exceptional culture – one that values integrity, collaboration, and the relentless pursuit of better outcomes for patients,” Melnyk said. “I’ve spent my career working to bring transformative oncology treatments to patients around the world. What excites me most about Taiho is the combination of deep scientific expertise, a mission-driven collaborative culture, and a shared commitment to making a difference for patients and their families.”
